* Drug will be commercially available in the US in Sept.
July 29 (Reuters) - Biopharmaceutical company Bristol-Myers Squibb Co (BMY.N) said the U.S. Food and Drug Administration approved a subcutaneous formulation of Orencia, a drug used to treat rheumatoid arthritis.
The company said the new self injectable formulation of Orencia will be commercially available in the U.S. in September 2011. An intravenous version of the drug was approved in 2005. (Reporting by Divya Sharma in Bangalore; editing by Carol Bishopric) (email@example.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: firstname.lastname@example.org))